Cited by 758Pluripotent Stem Cells ResearchOrgan and Tissue Transplantation ResearchMesenchymal stem cell research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

Open access

Deuse, Tobias, Hu, Xiaomeng, Gravina, Alessia, Wang, Dong, Tediashvili, Grigol, De, Chandrav, Thayer, William O., Wahl, Angela, Garcia, J. Victor, Reichenspurner, Hermann, Davis, Mark M., Lanier, Lewis L., Schrepfer, Sonja·2019·Nature Biotechnology

DOI 10.1038/s41587-019-0016-3PMC PMC6419516

Open this paper in CoChat — free account

Abstract

Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for patient-specific cell-based organ repair strategies. However, their generation and subsequent differentiation into specific cells or tissues entail cell line-specific manufacturing challenges and form a lengthy process that precludes acute treatment modalities. These shortcomings could be overcome by using prefabricated allogeneic cell or tissue products, but the vigorous immune response against histo-incompatible cells has prevented the successful implementation of this approach. Here we show that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. These hypoimmunogenic iPSCs retain their pluripotent stem cell potential and differentiation capacity. Endothelial cells, smooth muscle cells, and cardiomyocytes derived from hypoimmunogenic mouse or human iPSCs reliably evade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term without the use of immunosuppression. These findings suggest that hypoimmunogenic cell grafts can be engineered for universal transplantation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41587-019-0016-3

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature reviews. Immunology · doi:10.1038/nri2017 · Cited by 1,393
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1
Melkus, M. W., Estes, J. D., Padgett‐Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., Wege, A. K., Haase, A. T., & Garcia, J. V. (2006) · Nature Medicine · doi:10.1038/nm1431 · Cited by 653
Self-citation
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639
Fetomaternal immune cross-talk and its consequences for maternal and offspring's health
Arck, P., & Hecher, K. (2013) · Nature Medicine · doi:10.1038/nm.3160 · Cited by 609
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
Wunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415
Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
Chang, C., Fontes, J., Peterlin, M., & Flavell, R. (1994) · Journal of Experimental Medicine · doi:10.1084/jem.180.4.1367 · Cited by 352
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marbán, E., Aßmus, B., Henry, T. D., Traverse, J. H., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304346 · Cited by 313

Show all 31 references

Sorted by citations

The CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 760
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 746
Next-generation regulatory T cell therapy
Ferreira, L. M. R., Müller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 491
Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications
Doss, M. X., & Sachinidis, A. (2019) · Cells · doi:10.3390/cells8050403 · Cited by 486
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 451
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 472
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N. M., Hamieh, M., Hegde, M. G., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 318
Decellularization in Tissue Engineering and Regenerative Medicine: Evaluation, Modification, and Application Methods
Neishabouri, A., Soltani Khaboushan, A., Daghigh, F., Kajbafzadeh, A.-M., & Majidi Zolbin, M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.805299 · Cited by 281
Next-generation stem cells — ushering in a new era of cell-based therapies
Kimbrel, E. A., & Lanza, R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0064-x · Cited by 295
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials.
Zipser, C., Cragg, J., Guest, J., Fehlings, M., Jutzeler, C., Anderson, A., & Curt, A. (2022) · Lancet Neurology · doi:10.1016/s1474-4422(21)00464-6 · Cited by 212
Engineering universal cells that evade immune detection
Lanza, R., Russell, D. W., & Nagy, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0200-1 · Cited by 238
A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy
Iriguchi, S., Yasui, Y. Y., Kawai, Y., Arima, S., Kunitomo, M., Sato, T., Ueda, T., Minagawa, A., Mishima, Y., Yanagawa, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20658-3 · Cited by 210
Allogeneic natural killer cell therapy
Berrien-Elliott, M. M., Jacobs, M. T., & Fehniger, T. A. (2022) · Blood · doi:10.1182/blood.2022016200 · Cited by 242
CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy
Chang, Y., Cai, X., Syahirah, R., Yao, Y., Xu, Y., Jin, G., Bhute, V. J., Torregrosa‐Allen, S. E., Elzey, B. D., Won, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37872-4 · Cited by 245
Clinical Potential and Current Progress of Dental Pulp Stem Cells for Various Systemic Diseases in Regenerative Medicine: A Concise Review
Yamada, Y., Nakamura-Yamada, S., Kusano, K., & Baba, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051132 · Cited by 224
The SIRPα–CD47 immune checkpoint in NK cells
Deuse, T., Hu, X., Agbor-Enoh, S. T., Jang, M. K., Alawi, M., Saygı, C., Gravina, A., Tediashvili, G., Nguyen, V. Q., Liu, Y., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200839 · Cited by 210
Self-citation
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Tsuchida, C. A., Brandes, N., Bueno, R., Trinidad, M. I., Mazumder, T., Yu, B., Hwang, B., Chang, C. R., Liu, J., Sun, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.041 · Cited by 220
Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes
Hogrebe, N. J., Ishahak, M., & Millman, J. R. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.002 · Cited by 210
Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
Wang, B., Iriguchi, S., Waseda, M., Ueda, N., Ueda, T., Xu, H., Minagawa, A., Ishikawa, A., Yano, H., Ishi, T., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00730-z · Cited by 189
Advancing cell therapy for neurodegenerative diseases
Temple, S. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.03.017 · Cited by 221
CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids
Hendriks, D. F. G., Clevers, H. C., & Artegiani, B. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.10.014 · Cited by 202
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O. E., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S. M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 194
Dynamics and competition of CRISPR–Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing
Fu, Y.-W., Dai, X., Wang, W., Yang, Z.-X., Zhao, J.-J., Zhang, J., Wen, W., Zhang, F., Oberg, K. C., Zhang, L., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1251 · Cited by 182
Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
Kagoya, Y., Guo, T., Yeung, B., Saso, K., Anczurowski, M., Wang, C.-H., Murata, K., Sugata, K., Saijo, H., Matsunaga, Y., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0508 · Cited by 184
The evolving view of thermogenic adipocytes — ontogeny, niche and function
Shamsi, F., Wang, C., & Tseng, Y. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00562-6 · Cited by 184
Human Pluripotent Stem Cell-Derived Cardiovascular Cells: From Developmental Biology to Therapeutic Applications
Protze, S. I., Lee, J. H., & Keller, G. M. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.010 · Cited by 162
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques
Hu, X., White, K. A., Olroyd, A. G., DeJesus, R., Dominguez, A. A., Dowdle, W. E., Friera, A. M., Young, C., Wells, F., CHU, E. Y. L., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01784-x · Cited by 184
Self-citation
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
Jo, S., Das, S., Williams, A., Chrétien, A.-S., Pagliardini, T., Roy, A. L., Postigo, J., Clerre, D. L., Jahangiri, B., Chion-Sotinel, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30896-2 · Cited by 167
Engineered heart muscle allografts for heart repair in primates and humans
Jebran, A. F., Seidler, T., Tiburcy, M., Daskalaki, M., Kutschka, I., Fujita, B., Ensminger, S. M., Bremmer, F., Moussavi, A., Yang, H., et al. (2025) · Nature · doi:10.1038/s41586-024-08463-0 · Cited by 177
Immunological considerations and challenges for regenerative cellular therapies
Petrus-Reurer, S., Romano, M., Howlett, S., Jones, J., Lombardi, G., & Saeb‐Parsy, K. (2021) · Communications Biology · doi:10.1038/s42003-021-02237-4 · Cited by 165
Cell therapy for advanced liver diseases: repair or rebuild
Dwyer, B. J., Macmillan, M. T., Brennan, P. N., & Forbes, S. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.014 · Cited by 141
Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs
Luo, J., Qin, L., Zhao, L., Gui, L., Ellis, M. W., Huang, Y., Kural, M. H., Clark, J. A., Ono, S., Wang, J., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2019.12.012 · Cited by 150
3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells
Wang, Z., McWilliams‐Koeppen, H. P., Reza, H., Ostberg, J. R., Chen, W., Wang, X., Huynh, C., Vyas, V., Chang, W.-C., Starr, R., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.02.009 · Cited by 148
The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury
Ahuja, C. S., Mothe, A. J., Khazaei, M., Badhiwala, J. H., Gilbert, E. A. B., van der Kooy, D., Morshead, C. M., Tator, C. H., & Fehlings, M. G. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0135 · Cited by 148
GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
Leal, A. F., Benincore-Flórez, E., Solano-Galarza, D., Garzón-Jaramillo, R. G., Echeverri-Peña, O. Y., Súarez, D. A., Alméciga-Díaz, C. J., & Espejo-Mojica, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176213 · Cited by 138
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy
Nair, G. G., Tzanakakis, E. S., & Hebrok, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0375-3 · Cited by 134
Applications of iPSC-derived beta cells from patients with diabetes
Maxwell, K. G., & Millman, J. R. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100238 · Cited by 146
In vivo hitchhiking of immune cells by intracellular self-assembly of bacteria-mimetic nanomedicine for targeted therapy of melanoma
Cheng, G., Wang, Q., Li, J., Kwong, C. H. T., Wei, J., Xie, B., Lu, S., Lee, S. M., & Wang, R. (2022) · Science Advances · doi:10.1126/sciadv.abn1805 · Cited by 130
Targeting Natural Killer Cells for Tumor Immunotherapy
Zhang, C., Hu, Y., & Shi, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00060 · Cited by 128
Stem cell-derived cell sheet transplantation for heart tissue repair in myocardial infarction
Guo, R., Morimatsu, M., Tian, F., Lan, F., Chang, D., Wan, F., & Ling, Y. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1536-y · Cited by 123
Engineering islets from stem cells for advanced therapies of diabetes
Siehler, J., Blöchinger, A. K., Meier, M., & Lickert, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00262-w · Cited by 125
Partners in Crime: Beta-Cells and Autoimmune Responses Complicit in Type 1 Diabetes Pathogenesis
Toren, E., Burnette, K., Banerjee, R. R., Hunter, C. S., & Tse, H. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.756548 · Cited by 115
Heart regeneration: 20 years of progress and renewed optimism
Garbern, J. C., & Lee, R. T. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.012 · Cited by 115
Graphene-Based Scaffolds for Regenerative Medicine
Bellet, P., Gasparotto, M., Pressi, S., Fortunato, A., Scapin, G., Mba, M., Menna, E., & Filippini, F. (2021) · Nanomaterials · doi:10.3390/nano11020404 · Cited by 116
Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates
Meng, Q., Tai, W., Tian, M., Zhuang, X., Pan, Y., Lai, J., Xu, Y., Xu, Z., Li, M., Zhao, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3277 · Cited by 114
De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans
Deuse, T., Hu, X.-M., Agbor-Enoh, S., Koch, M., Spitzer, M., Gravina, A., Alawi, M., Marishta, A., Peters, B., Koşaloğlu-Yalçın, Z., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0227-7 · Cited by 101
Self-citation
Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards
Martin, R. M., Fowler, J. L., Cromer, M. K., Lesch, B. J., Ponce, E., Uchida, N., Nishimura, T., Porteus, M. H., & Loh, K. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16455-7 · Cited by 110
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance
Müller, Y. D., Ferreira, L. M. R., Ronin, É., Ho, P., Nguyen, V. Q., Faleo, G., Zhou, Y., Lee, K., Leung, K., Skartsis, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686439 · Cited by 109
The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles
Jarrige, M., Frank, E., Herardot, E., Martineau, S., Darle, A., Benabidès, M., Domingues, S., Chose, O., Habeler, W., Lorant, J., et al. (2021) · Cells · doi:10.3390/cells10020240 · Cited by 107
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
Gouda, N. A., Elkamhawy, A., & Cho, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020371 · Cited by 112
Towards stem cell therapies for skeletal muscle repair
Judson, R. N., & Rossi, F. M. V. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-0094-3 · Cited by 109
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes
Cai, E. P., Ishikawa, Y., Zhang, W., Leite, N. C., Li, J., Hou, S., Kiaf, B., Hollister‐Lock, J., Yılmaz, N. K., Schiffer, C. A., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0254-1 · Cited by 107
Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice
Hu, X., Gattis, C., Olroyd, A. G., Friera, A. M., White, K. A., Young, C., Basco, R., Lamba, M., Wells, F., Ankala, R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg5794 · Cited by 104
Self-citation
Machine perfusion of the liver and bioengineering
Schlegel, A. A., Mergental, H., Fondevila, C., Porte, R. J., Friend, P. J., & Dutkowski, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.009 · Cited by 106
Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities
Kim, T. W., Koo, S. Y., & Studer, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00729 · Cited by 101
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 96
The blood–brain barrier: a help and a hindrance
Rust, R., Yin, H. R., Buil, B. A., Sagare, A. P., & Kisler, K. (2025) · Brain · doi:10.1093/brain/awaf068 · Cited by 109
Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection
Parent, A. V., Faleo, G., Chavez, J., Saxton, M., Berrios, D. I., Kerper, N. R., Tang, Q., & Hebrok, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109538 · Cited by 96
iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine
Olgasi, C., Cucci, A., & Follenzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176215 · Cited by 100
Survival of transplanted allogeneic beta cells with no immunosuppression
Carlsson, P.-O., Hu, X., Scholz, H., Ingvast, S., Lundgren, T., Scholz, T., Eriksson, O., Liss, P., Yu, D., Deuse, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503822 · Cited by 84
Self-citation
iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
Attwood, S. W., & Edel, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030288 · Cited by 99
Stem Cell-Based Therapies for Parkinson Disease
Liu, Z., & Cheung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218060 · Cited by 98
Advancing cell-based cancer immunotherapy through stem cell engineering
Li, Y.-R., Dunn, Z. S., Yu, Y., Li, M., Wang, P., & Yang, L. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.02.009 · Cited by 95
Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification
Augsornworawat, P., Hogrebe, N. J., Ishahak, M., Schmidt, M. D., Marquez, E., Maestas, M. M., Veronese-Paniagua, D., Gale, S. E., Miller, J. R., Velazco-Cruz, L., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01150-8 · Cited by 91
Replacing what’s lost: a new era of stem cell therapy for Parkinson’s disease
Fan, Y., Winanto, W., & Ng, S. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-019-0180-x · Cited by 90
Biomanufacturing human tissues via organ building blocks
Wolf, K. J., Weiss, J. D., Uzel, S. G. M., Skylar‐Scott, M. A., & Lewis, J. A. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.04.012 · Cited by 94
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Hu, X.-M., Manner, K., deJesus, R., White, K., Gattis, C., Ngo, P., Bandoro, C., Tham, E., Chu, E. Y., Chi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37785-2 · Cited by 81
Self-citation
Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy
Courtney, A. N., Tian, G., & Metelitsa, L. S. (2022) · Blood · doi:10.1182/blood.2022016201 · Cited by 87
High-throughput genome-wide phenotypic screening via immunomagnetic cell sorting
Mair, B., Aldridge, P. M., Atwal, R. S., Philpott, D. N., Zhang, M., Masud, S. N., Labib, M., Tong, A. H. Y., Sargent, E. H., Angers, S., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0454-8 · Cited by 84
Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations
Desgres, M., & Menasché, P. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.10.001 · Cited by 88
Harnessing the biology of regulatory T cells to treat disease
Wardell, C. M., Boardman, D. A., & Levings, M. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01089-x · Cited by 91
Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectives
Demirci, S., Leonard, A., & Tisdale, J. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0247 · Cited by 63
iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity
Suzuki, D., Flahou, C., Yoshikawa, N., Stirblytė, I., Hayashi, Y., Sawaguchi, A., Akasaka, M., Nakamura, S., Higashi, N., Xu, H., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.11.011 · Cited by 81
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells
Leite, N. C., Sintov, E., Meissner, T. B., Brehm, M. A., Greiner, D. L., Harlan, D. M., & Melton, D. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107894 · Cited by 78
Context-aware synthetic biology by controller design: Engineering the mammalian cell
Shakiba, N., Jones, R. D., Weiss, R., & Vecchio, D. D. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.011 · Cited by 78
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 81
Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application
Kitano, Y., Nishimura, S., Kato, T., Ueda, A., Takigawa, K., Umekage, M., Nomura, M., Kawakami, A., Ogawa, H., Xu, H., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.05.010 · Cited by 80
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 88
A Short History of Skin Grafting in Burns: From the Gold Standard of Autologous Skin Grafting to the Possibilities of Allogeneic Skin Grafting with Immunomodulatory Approaches
Schlottmann, F., Bucan, V., Vogt, P. M., & Krezdorn, N. (2021) · Medicina · doi:10.3390/medicina57030225 · Cited by 79
Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy
Lian, S., Xie, X., Lu, Y., & Lee, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s220196 · Cited by 74
Cell–drug conjugates
Wang, Y., Shi, J., Xin, M., Kahkoska, A. R., Wang, J., & Gu, Z. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01230-6 · Cited by 82
Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II
Petrus-Reurer, S., Winblad, N., Kumar, P., Gorchs, L., Chrobok, M., Wagner, A. K., Bartuma, H., Lardner, E., Aronsson, M., Reyes, Á. P., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.02.006 · Cited by 72
Sensing and clearance of apoptotic cells
Nagata, S., & Segawa, K. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.07.007 · Cited by 71
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
Li, Y.-R., Zhou, Y., Yu, J., Zhu, Y., Lee, D., Zhu, E., Li, Z., Kim, Y. J., Zhou, K., Fang, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.005 · Cited by 73
Delivering living medicines with biomaterials
Harimoto, T., Jung, W., & Mooney, D. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-024-00766-y · Cited by 79
Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
Ford, E., Pearlman, J., Ruan, T., Manion, J., Waller, M. A., Neely, G. G., & Caron, L. (2020) · Cells · doi:10.3390/cells9112517 · Cited by 71
Current status and future perspectives of HLA-edited induced pluripotent stem cells
Koga, K., Wang, B., & Kaneko, S. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00132-9 · Cited by 70
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 71
The Challenge of Bringing iPSCs to the Patient
Ortuño‐Costela, M. D. C., Cerrada, V., García‐López, M., & Gallardo, M. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246305 · Cited by 73
Rapid generation of functional vascular organoids via simultaneous transcription factor activation of endothelial and mural lineages
Gong, L., Zhang, Y., Zhu, Y., Lee, U., Luo, A. C., Li, X., Wang, X., Chen, D., Pu, W. T., Lin, R., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.05.014 · Cited by 73
Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes
Goswami, D., Domingo‐Lopez, D. A., Ward, N. A., Millman, J. R., Duffy, G. P., Dolan, E. B., & Roche, E. T. (2021) · Advanced Science · doi:10.1002/advs.202100820 · Cited by 72
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Lv, Z., Luo, F., & Chu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199145 · Cited by 70
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Pruß, A., Schmueck-Henneresse, M., Volk, H.-D., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02928-7 · Cited by 65
Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins
Shi, L., Li, W., Liu, Y., Chen, Z., Hui, Y., Hao, P., Xu, X., Zhang, S., Feng, H., Zhang, B., et al. (2020) · Stem Cells · doi:10.1002/stem.3269 · Cited by 63
The future of stem cell therapies of Alzheimer’s disease
Wang, Z., Wang, Z.-T., Sun, Y., Tan, L., & Yu, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101655 · Cited by 65
The Challenges to Advancing Induced Pluripotent Stem Cell-Dependent Cell Replacement Therapy
Moy, A. B., Kamath, A. M., Ternes, S., & Kamath, J. (2023) · Medical Research Archives · doi:10.18103/mra.v11i11.4784 · Cited by 74
Brain repair mechanisms after cell therapy for stroke
Rust, R., Nih, L. R., Liberale, L., Yin, H. R., Amki, M. E., Ong, L. K., & Zloković, B. V. (2024) · Brain · doi:10.1093/brain/awae204 · Cited by 65
Endometrial stromal cells exhibit a distinct phenotypic and immunomodulatory profile
Queckbörner, S., Lundberg, E. S., Gemzell‐Danielsson, K., & Davies, L. C. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1496-2 · Cited by 59

Authors: Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., Davis, M. M., Lanier, L. L., & Schrepfer, S.
Affiliations: University of California, San Francisco (US)
Universität Hamburg (DE)
University of North Carolina at Chapel Hill (US)
Howard Hughes Medical Institute (US)
Corresponding author: Schrepfer, Sonja
ORCID: Deuse, Tobias
Hu, Xiaomeng
Gravina, Alessia
Wang, Dong
Tediashvili, Grigol
De, Chandrav
Wahl, Angela
Davis, Mark M.
Lanier, Lewis L.
Schrepfer, Sonja
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-18
Volume: 37
Issue: 3
Pages: 252-258
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/s41587-019-0016-3
PMC: PMC6419516
OpenAlex: W2911604931
Cited by: 758
References: 31
Citations by year: 2026: 98 · 2025: 102 · 2024: 102 · 2023: 113 · 2022: 94 · 2021: 97 · 2020: 106 · 2019: 46
FWCI: 28.36
Type: journal article
Language: en
Update notices: correction (2022-09-16)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Heart, Lung, and Blood Institute (R01HL140236)
National Institute of Mental Health (R01MH108179)
National Institute of Allergy and Infectious Diseases (R01AI068129, R01AI111899, R01AI123010, U19AI057229)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords: induced pluripotent stem cells, immune rejection, allogeneic transplantation, MHC mismatch, endothelial cells, smooth muscle cells, cardiomyocytes, immunosuppression-free transplantation
MeSH terms: Animals, Cell Differentiation, Graft Rejection, HLA Antigens, Humans, Transplantation, Homologous, Histocompatibility Antigens Class I, Myocytes, Cardiac, Mice, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks